Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. (Record no. 24197506)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02374 a2200613 4500 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250516233525.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 201507s 0 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1557-3265 |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1158/1078-0432.CCR-14-1511 |
Source of number or code | doi |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | NLM |
Language of cataloging | eng |
Transcribing agency | NLM |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Katayama, Ryohei |
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Date of production, publication, distribution, manufacture, or copyright notice | 20150709 |
245 00 - TITLE STATEMENT | |
Title | Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. |
Medium | [electronic resource] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Name of publisher, distributor, etc. | Clinical cancer research : an official journal of the American Association for Cancer Research |
Date of publication, distribution, etc. | Nov 2014 |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 5686-96 p. |
Other physical details | digital |
500 ## - GENERAL NOTE | |
General note | Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Anaplastic Lymphoma Kinase |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Benzoquinones |
General subdivision | pharmacology |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Carbazoles |
General subdivision | pharmacology |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Carcinoma, Non-Small-Cell Lung |
General subdivision | diagnostic imaging |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Cell Line, Tumor |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Crizotinib |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | DNA Mutational Analysis |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Dose-Response Relationship, Drug |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Drug Resistance, Neoplasm |
General subdivision | genetics |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | HSP90 Heat-Shock Proteins |
General subdivision | antagonists & inhibitors |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Humans |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Inhibitory Concentration 50 |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Lactams, Macrocyclic |
General subdivision | pharmacology |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Lung Neoplasms |
General subdivision | diagnostic imaging |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Models, Molecular |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Mutation |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Piperidines |
General subdivision | pharmacology |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Protein Conformation |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Protein Kinase Inhibitors |
General subdivision | pharmacology |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Pyrazoles |
General subdivision | pharmacology |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Pyridines |
General subdivision | pharmacology |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Receptor Protein-Tyrosine Kinases |
General subdivision | antagonists & inhibitors |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Tomography, X-Ray Computed |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Friboulet, Luc |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Koike, Sumie |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Lockerman, Elizabeth L |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Khan, Tahsin M |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Gainor, Justin F |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Iafrate, A John |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Takeuchi, Kengo |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Taiji, Makoto |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Okuno, Yasushi |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Fujita, Naoya |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Engelman, Jeffrey A |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Shaw, Alice T |
773 0# - HOST ITEM ENTRY | |
Title | Clinical cancer research : an official journal of the American Association for Cancer Research |
Related parts | vol. 20 |
-- | no. 22 |
-- | p. 5686-96 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://doi.org/10.1158/1078-0432.CCR-14-1511">https://doi.org/10.1158/1078-0432.CCR-14-1511</a> |
Public note | Available from publisher's website |
No items available.